Share on StockTwits

Shares of Tornier NV (NASDAQ:TRNX) have received a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the company, Stock Ratings Network reports. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $22.67.

TRNX has been the subject of a number of recent research reports. Analysts at Piper Jaffray raised their price target on shares of Tornier NV from $25.00 to $26.00 in a research note on Friday. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Tornier NV from $20.00 to $23.00 in a research note on Friday. Finally, analysts at Barclays raised their price target on shares of Tornier NV from $26.00 to $28.00 in a research note on Friday.

Shares of Tornier NV (NASDAQ:TRNX) opened at 21.59 on Friday. Tornier NV has a 52 week low of $15.17 and a 52 week high of $24.35. The stock’s 50-day moving average is $22.16 and its 200-day moving average is $20.55. The company’s market cap is $1.056 billion.

Tornier NV (NASDAQ:TRNX) last released its earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Analysts expect that Tornier NV will post $-0.54 EPS for the current fiscal year.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.